Where Singapore Fits and Where It Does Not

2.1 Why This Chapter Comes Before the Detail

A European industrialist deciding where to place a biomedical operation does not need to be told that Singapore is impressive. The figures are easy to find and the agencies publish them readily. What the industrialist needs, and what is harder to come by, is an honest account of which functions belong in Singapore and which do not. That account is the purpose of this chapter, and it comes before the chapters on tax, on regulation, on land, and on staffing because it frames all of them. There is no point optimising a tax structure for an activity that should never have been placed in Singapore in the first place.

The honest position is straightforward. Singapore has built a biomedical sector of real depth, but it has built it along a particular axis. The axis runs through complexity, intellectual property, regulatory credibility, and regional reach. It does not run through volume, through cost, or through scale of population. Functions that sit on the first axis fit well. Functions that sit on the second do not, and they fit better in India, in Malaysia, or in China. A European firm whose competitive position rests on a high-value, IP-intensive product will often find Singapore an excellent answer. A European firm whose product competes on price per unit will usually find it the wrong one.

This is the same discipline applied in the first book in this series, on Singapore manufacturing more generally. Honesty about the wrong answer is the strongest available signal of competence about the right one. A reader who is told only what Singapore does well has been given a brochure. A reader who is told where Singapore underperforms an alternative, and why, has been given something usable.

The chapter assesses eight functions in turn. The first five are functions for which the evidence supports a strong fit. The sixth and seventh are mixed, fitting for some uses and not for others. The eighth is the supporting ecosystem. After the function-by-function assessment, the chapter consolidates the no-fit cases, because they carry the most weight for a reader who is about to spend money, and closes with the recurring mistakes European firms make in reading the boundary.

2.2 The Scale of the Sector, Stated Plainly

Before the function-by-function assessment, the size of the thing. Singapore’s biomedical industry comprises two sectors, biopharmaceuticals and medical technology, and the published output figures give a sense of scale that is useful as a backdrop rather than as a selling point.

The Economic Development Board, the agency that has cultivated the sector for more than two decades and remains the first point of contact for most inbound biomedical investment, states that biopharmaceutical manufacturing output exceeded eighteen billion Singapore dollars in 2023, having roughly doubled over the preceding two decades.¹ The medical technology sector reached a manufacturing output of nineteen point four billion Singapore dollars in 2023, up from five point two billion a decade earlier in 2013.² Taken together, biomedical manufacturing generated output of around thirty-eight billion Singapore dollars in 2023 and accounted for roughly two point six per cent of gross domestic product.³

Two facts behind the headline figures matter more than the figures themselves. The first is that eight of the world’s ten largest biopharmaceutical companies operate manufacturing facilities in Singapore, and that the country hosts more than sixty biopharmaceutical manufacturing plants across modalities ranging from small-molecule active pharmaceutical ingredients through biologics to newer formats such as cell therapies and antibody-drug conjugates.⁴ The second is that the medical technology sector rests on a base of more than four hundred companies and a supporting layer of more than two thousand seven hundred precision engineering and electronics manufacturing services providers, with around seventy per cent of medical technology manufacturers conducting research and development locally rather than treating Singapore as a pure production site.⁵ The density of that supporting layer is part of why the high-value functions fit, and its absence in the commodity segments is part of why the low-value functions do not.

A note on the figures is warranted here and applies throughout the book. Output numbers from different sources do not always agree, because they measure slightly different things over slightly different periods. An independent analysis of the sector placed 2023 biopharmaceutical output at a lower figure than the Economic Development Board’s, closer to fourteen billion Singapore dollars on one measure.⁶ Where the agency’s own published figure and an independent figure diverge, this book reports the divergence rather than choosing the more flattering number. The agency figure is the primary for Singapore’s own account of itself; the independent figure is a reminder that a single headline number should not carry a location decision.

2.3 Early-Stage and Translational Research: A Strong Fit

The clearest fit is for discovery and translational research. This is the activity Singapore has subsidised most deliberately and for the longest, and the public commitment is large and current. Under the Research, Innovation and Enterprise 2030 plan, the government has committed thirty-seven billion Singapore dollars to science and technology development, with health and biomedical sciences as one of the named domains.⁷ A European biotechnology firm placing a discovery or translational function in Singapore is placing it inside a system that the state is actively funding rather than merely tolerating.

The basis of the fit is not only money. It is the co-location of public research institutes, corporate laboratories, and the talent that moves between them, concentrated in the Biopolis research cluster and the surrounding estates. The state’s research agency, the Agency for Science, Technology and Research, anchors a network of research institutes that a corporate laboratory can draw on for collaboration and for recruitment.⁸ For a European firm, the practical meaning is that early-stage work placed in Singapore does not sit in isolation. It sits next to public capability, and the boundary between the two is porous in a way that is deliberate policy rather than accident.

Intellectual property protection is the other pillar, and it is the one European firms tend to weigh most heavily. The reason a firm whose value rests on a formulation, a sequence, or a process will consider Singapore for that work at all is that the legal environment is one in which the firm expects to keep what it develops. This is treated in detail in a later chapter; for the purposes of the use-case assessment, it is enough to say that strong and enforceable intellectual property protection is the precondition that makes the research fit real rather than nominal. Without it, the funding and the co-location would attract commodity work and nothing else.

The honest qualification on the research fit concerns scale and cost. Singapore is well suited to high-value, high-IP research conducted by a relatively small and expensive team. It is not suited to research that depends on a large, low-cost workforce, and a European firm whose research model is labour-extensive rather than capability-intensive will find the economics unfavourable. The fit is for the laboratory of fifty highly paid scientists, not for the operation of five hundred technicians.

2.4 Clinical-Grade and High-Value Manufacturing: A Strong Fit

The second strong fit is for the manufacture of complex, high-value therapeutic products: biologics, vaccines, cell therapies, and antibody-drug conjugates. Here the evidence is in the form of investment decisions by firms that had the whole world to choose from, and the most recent large decision is instructive.

In 2024 AstraZeneca committed one point five billion United States dollars to a fifty-eight-acre site in Tuas South to build what it describes as its first end-to-end manufacturing facility for antibody-drug conjugates anywhere in the world, with operational readiness targeted for 2029 and a planned workforce of more than eight hundred in skilled engineering, quality, technical, and supply-chain roles.⁹ An antibody-drug conjugate is among the most process-intensive products in modern medicine, requiring antibody production, the synthesis of a cytotoxic payload and a chemical linker, the conjugation of the two, and sterile fill of the finished substance, all under exacting control. A firm does not place that activity where it lacks confidence in the process workforce, the utilities, and the regulatory environment. The decision is a statement about fit for complexity.

The pattern repeats across the cluster. The contract development and manufacturing organisation Lonza commenced large-scale mammalian biologics production in Singapore in 2011 with a twenty-thousand-litre stainless-steel capacity and added a two-thousand-litre single-use line in 2018, and it operates a cell-therapy site alongside the biologics facility producing monoclonal antibodies, recombinant proteins, and allogeneic cell therapy products.¹⁰ The relevant point is the modality, not the headcount. These are the high-complexity formats that fit Singapore, and the firms that make them have chosen to make them there.

The basis of the fit is a combination of dedicated infrastructure and a workforce capable of running it. The Tuas Biomedical Park, master-planned and developed by the industrial land agency, provides ready-built facilities, shared utilities, and proximity that a greenfield builder would otherwise have to assemble from scratch.¹¹ The cost qualification is important and is the hinge on which the whole chapter turns: baseline operating costs in Singapore are high, and the sector absorbs them only because the products are high-value and the facilities are designed to minimise consumption. The economics work for a biologic worth thousands of dollars per gram. They do not work for a product worth cents per unit. This is the boundary, and it is stated again in the no-fit section below because it is the single most consequential fact in the chapter.

2.5 Regulatory Affairs and Regional Market Access: A Strong Fit

The third strong fit is the one a European firm is most likely to underestimate, because it is not about making anything. It is about the value of basing the regulatory and market-access function for the Asia-Pacific region in a jurisdiction whose regulator is internationally trusted.

Singapore’s medicines and medical-device regulator is the Health Sciences Authority, and its standing is not a matter of reputation alone but of formal international recognition. In 2022 the Health Sciences Authority became the first regulatory authority in the world to attain the World Health Organization’s highest maturity level, Maturity Level 4, for its medicines regulatory system, and in 2023 it was recognised as a WHO-Listed Authority.¹² In March 2026 it became the first national regulatory authority in the world to attain Maturity Level 4 for medical devices as well, announced at the twenty-ninth session of the International Medical Device Regulators Forum, which Singapore hosted.¹³ These are not ceremonial designations. They mean that other regulators may rely on the Health Sciences Authority’s assessments, which is the mechanism through which a Singapore approval can shorten the path to approval elsewhere.

For a European firm, the practical value is twofold. First, a regulatory approval obtained through a reference authority carries weight in other markets that recognise reliance pathways, so the regulatory work done in Singapore is not confined to the Singapore market. Second, Singapore participates in arrangements such as the Access Consortium, through which it works with the regulators of the United Kingdom, Australia, Canada, and Switzerland, and these arrangements support abridged review for products already assessed by a trusted counterpart.

[DAVID: This section would benefit from a short practitioner observation on how European firms actually use a Singapore regulatory base in practice. The primary sources establish the HSA’s standing and the existence of reliance and Access Consortium pathways, but they do not describe the day-to-day reality of how a European medical device or pharmaceutical firm sequences a Singapore regional regulatory HQ against its home-market filings. If you have a representative example from your practice or your network of how this sequencing has worked, it would anchor the section. Absent that, the section stays at the level the primaries support.]

The honest qualification is that regulatory credibility is necessary but not sufficient. A firm that bases its regulatory function in Singapore still has to do the substantive work of meeting each market’s requirements, and the reliance pathways shorten time rather than eliminating effort. The value is real but it is a value of acceleration and credibility, not of exemption.

2.6 Regional Distribution: A Strong Fit

The fourth strong fit follows from geography and infrastructure rather than from policy. Singapore functions as a regional distribution hub for Southeast Asia, and for time-sensitive medical products the combination of Changi Airport’s air-freight capacity and the port’s container infrastructure makes it a natural base for the regional commercial and logistics function. The domestic market is small, but the function being placed in Singapore is not service of the domestic market; it is service of the broader region from a single well-connected node.

The basis of the fit is the same density that supports manufacturing: a concentration of logistics capability, customs and trade arrangements that reduce friction across the regional market, and the presence of the regional headquarters of a large number of the global firms whose products move through the hub. For a European medical-device firm in particular, basing the regional distribution and commercial function in Singapore places it close to its regulatory function and to the regulators on whom regional approvals depend, which is an organisational convenience that compounds over time.

The qualification here is modest. Distribution from Singapore serves the region well, but a firm whose volumes are concentrated in a single large national market within the region may find it more efficient to distribute closer to that market. The hub model fits a firm serving the region as a whole; it fits less well a firm whose demand is lumpy and national.

2.7 Clinical Trials: A Qualified Fit

The fifth function is the first of the mixed cases, and the qualification is sharp enough to be worth stating precisely. Singapore is an excellent location for early-phase clinical work and a poor location for stand-alone large-scale efficacy trials, and the reason is arithmetic before it is anything else.

The strength is in early-phase and specialised work. Singapore’s academic medical centres and research institutes support Phase I and Phase II studies, pharmacokinetic profiling, and specialised oncology and cell-therapy trials at a high level of analytical depth. The national research funder, the National Medical Research Council, directs competitive funding toward early-phase trials of high translational value, with oncology and cardiology among the explicit priorities, and toward smaller regional network trials for diseases of particular relevance to Singapore and Asia.¹⁴ A European firm with an early-phase oncology or cell-therapy programme will find genuine capability here.

The weakness is in scale. A large Phase III efficacy trial requires the recruitment of thousands of patients across diverse cohorts within a reasonable period, and Singapore’s resident population, around four point two million people within a total population of about six point one million, simply does not provide the raw recruitment base for rapid enrolment at that scale.¹⁵ This is not a deficiency that funding or policy can correct; it is a fact of size. A European firm that needs a stand-alone Phase III trial run quickly will not find Singapore the place to run it. The practical model, and the one the ecosystem is built around, is to use Singapore as one site within a larger multi-regional trial, contributing analytical quality and specific cohorts rather than bulk recruitment.

There is a further qualification on generalisability that an honest assessment should not omit. The demographic composition of trial cohorts in Singapore does not always mirror the national population, with published analyses noting under-representation of certain groups, which bears on how far results from Singapore alone can be generalised. The point is not that Singapore conducts poor trials; it is that a small and particular population constrains both the speed and the representativeness of large efficacy work, and a firm planning its trial strategy should treat Singapore as a specialist contributor rather than a volume site.

[DAVID: If you have practitioner-side observation on how European sponsors actually structure the Singapore leg of a multi-regional trial, or on how the early-phase strength is used as an entry point that later anchors a wider relationship, it would strengthen this section. The primaries support the early-phase strength and the Phase III scale constraint; they are silent on the commercial sequencing.]

2.8 Medical-Device Operations: A Split Verdict

The sixth function divides cleanly along the same axis as manufacturing generally, and the split is worth stating as a split rather than as a single verdict. For high-value, specialised devices the fit is strong. For high-volume, low-value consumables it is poor.

The strong side is well evidenced. The medical technology sector’s nineteen point four billion Singapore dollar output in 2023 is concentrated in high-margin, specialised products, and the named operators illustrate the type.¹⁶ The genomics firm Illumina operates research and manufacturing in Singapore. Edwards Lifesciences manufactures structural heart valves there and works with a homegrown manufacturing partner to design and build tooling. Leica Microsystems opened a facility for surgical microscopes, and the German cardiac-rhythm-management firm Biotronik established an Asia-Pacific manufacturing and research hub in late 2023.¹⁷ These are precision products with high engineering content and high unit value, and the supporting base of precision engineering firms is exactly what they require. A European device firm with a comparable product profile is the natural candidate for a Singapore operation.

The poor side is equally clear and is acknowledged in Singapore’s own policy. For high-volume, lower-value consumables, the state does not pretend the economics work in Singapore. It actively promotes a twinning model in which high-value development and high-IP work remain in Singapore while high-volume assembly and packaging are carried out in neighbouring Malaysia, taking advantage of lower production costs there while keeping the defensible intellectual property in Singapore. A European firm whose device is a high-volume consumable should expect, on the evidence, to be guided toward exactly this split rather than toward a wholly Singapore-based operation.

2.9 The Supporting Ecosystem: A Strong Fit

The seventh assessment concerns the firms that exist to serve other firms: contract research organisations, contract development and manufacturing organisations, central and bioanalytical laboratories, and regulatory consultancies. The fit here is strong, and it is strong for a particular reason that bears on the European reader’s own choices.

These firms fit Singapore because they do not compete on raw facility footprint. A contract development and manufacturing organisation specialising in mammalian cell culture or in clinical-to-commercial biologics manufacture is selling process capability, regulatory compliance, and analytical depth, not square metres of low-cost floor space. That is precisely the kind of value Singapore’s cost structure supports. Global contract research organisations operate central and bioanalytical laboratories in Singapore to manage multi-site trials across the region under international good-laboratory-practice and good-clinical-practice standards, and global contract development and manufacturing organisations operate biologics and cell-therapy facilities for the same reason the originator firms do: the work is complex and high-value, and the environment is built for it.

For a European firm, the practical significance is that the supporting ecosystem is available as an alternative to building. A firm that wants Singapore’s regulatory credibility and process capability for a biologic, but does not want to construct and staff its own plant, can contract for the capability rather than owning it. The ecosystem’s strength is what makes a capital-light entry into Singapore feasible, and for many European firms a contracted entry is the right first step rather than a greenfield facility.

2.10 The No-Fit Cases, Stated Without Hedging

The functions assessed above range from strong fit to qualified fit. This section is about the functions for which Singapore is the wrong answer, and it is the most important section in the chapter. A European firm that absorbs nothing else should absorb this: there are biomedical activities that Singapore cannot do economically, will not subsidise, and quietly directs elsewhere, and a firm that places one of them in Singapore has made an error that no amount of subsequent optimisation will repair.

The first no-fit case is high-volume, low-margin commodity manufacturing: generic small-molecule active pharmaceutical ingredients and finished dosage forms competing on price, and disposable medical consumables. The reason is structural and Singapore states it plainly. The country has a compact land area, high utility overheads, and premium salary expectations, and commodity manufacturing, which depends on large industrial footprints, low-wage labour, and high consumption of water and electricity, cannot absorb those costs. This is not a policy choice that might change; it is a feature of a small, expensive, high-income economy.

Where, then, should these functions go? The honest answer names the alternatives. For high-volume generic active pharmaceutical ingredients and finished dosage forms, India is the established low-cost location. A peer-reviewed analysis of pharmaceutical manufacturing costs found that producing for a less stringently regulated market in India incurred around forty-three per cent lower capital expenditure and forty-seven per cent lower operating expenditure than producing for a highly regulated market such as the United States, a gap driven by regulatory stringency, labour cost, and infrastructure economics.¹⁸ The comparison there is India against highly regulated Western production rather than against Singapore specifically, but the direction is unambiguous and the gap is large. India produces roughly a fifth of the world’s generic drugs by volume and competes precisely on the cost axis that Singapore does not occupy.¹⁹

For high-volume secondary processing, assembly, and packaging of devices and formulations, Malaysia is the established twinning partner, and as noted above Singapore’s own policy promotes the split rather than resisting it. For deep supply-chain integration and the largest scale, China remains dominant: a World Bank estimate cited in the literature put the API cost advantage of China and India over the United States and Europe at around forty per cent, and China is estimated to control a very large share of the global generic active-pharmaceutical-ingredient supply chain through scale, vertical integration, and sustained state support.²⁰

The point of naming these alternatives is not to diminish Singapore. It is the opposite. Singapore has chosen not to compete for commodity manufacturing because it has chosen to compete for complexity, credibility, and intellectual property instead, and the two strategies are mutually exclusive at the level of a single facility. A European firm that understands the choice can place its commodity work where commodity work belongs and its high-value work where high-value work belongs, which is very often a split across two or three countries with Singapore holding the high-IP centre. A firm that does not understand the choice will try to do everything in one place and will get the economics wrong wherever it lands.

The second no-fit case has already been stated and is restated here for completeness: stand-alone large-scale Phase III efficacy trials, which the resident population cannot support at speed and which belong in a multi-regional structure with Singapore as one specialist site rather than the whole.

2.11 A Note on How the Agencies Engage

A European reader will reasonably ask how a firm actually enters this system: who is called first, how a relationship with the agencies develops, and how the case-management that the largest investments evidently receive actually works in practice. It is worth being honest about the limits of what the primary sources establish.

What the sources establish is that the Economic Development Board is the lead agency for inbound biomedical investment and has cultivated the sector for over two decades; that the industrial land agency develops and allocates the specialised estates such as Tuas Biomedical Park; that the Health Sciences Authority regulates products and is expanding an economic-development role alongside its regulatory function;¹³ and that the research agency and the national research funder direct the public research and trial funding. These are the institutions, and their published roles are clear.

What the sources do not establish, and what this chapter will therefore not invent, is the texture of the engagement: which official a particular firm contacts first, how quickly a serious enquiry is met, how an incentive package is actually negotiated, and how the facilitation that large investors plainly receive is organised behind the published announcements. That the agencies actively facilitate significant inbound investment is evident from the scale and speed of the decisions described in this chapter; the published record describes the outcomes and the responsiveness, not the internal process. This is facilitation and responsiveness, not favouritism, and the distinction matters: the agencies implement industrial policy, and a firm that fits the policy finds them responsive because responsiveness to fitting investment is the policy.

[DAVID: This is the practitioner heart of the chapter’s engagement question, and the primaries are deliberately silent on it. What can you add from direct experience about how a European biomedical firm actually makes first contact and develops the relationship with EDB and the other agencies? Even a careful, non-specific account of the realistic first steps and the tempo of engagement would fill a gap the published sources leave open. Please keep it within what you can stand behind, in the language of facilitation rather than influence.]

2.12 The Mistakes European Firms Make in Reading the Boundary

The recurring errors are errors of category. A firm that places a function on the wrong side of the boundary between complexity and volume rarely recovers the decision cheaply. The following are the mistakes seen most often.

Treating Singapore as a single answer rather than a function-by-function one. The commonest error is to ask whether to go to Singapore, rather than which functions to place there. The right question is always granular, because the sector is granular: research and high-value manufacturing fit, commodity work does not, and the same firm may belong in Singapore for one activity and in India for another.

Bringing commodity manufacturing and expecting the cost base to work. A firm whose product competes on price per unit, whether a generic active ingredient or a disposable consumable, will not make the economics work in Singapore, and no incentive package closes a structural cost gap of the magnitude described above. The error is to be persuaded by the strength of the high-value cluster that the cost base is manageable for low-value work. It is not.

Planning a stand-alone Phase III trial around the Singapore population. A firm that treats Singapore as a primary recruitment site for a large efficacy trial will under-recruit and over-run. Singapore is a specialist site within a multi-regional trial, strong in early phase and in specific cohorts, not a volume recruiter.

Undervaluing the regulatory base because it produces nothing. A firm focused on manufacturing may treat the regulatory and market-access function as an afterthought and place it for convenience rather than for advantage. Given the Health Sciences Authority’s reference-authority standing, the regulatory base is one of the highest-value functions a firm can locate in Singapore, and locating it carelessly forgoes real acceleration in other markets.

Building when contracting would do. A firm that assumes Singapore entry means a greenfield facility overlooks the depth of the contract development and manufacturing ecosystem. For many firms the right first step is a contracted entry that secures Singapore’s process capability and regulatory credibility without the capital and staffing of an owned plant.

Resisting the Malaysia twinning model. A device firm with a high-volume component may treat the Singapore-Malaysia split as a compromise to be avoided rather than the intended design. The split is the policy; fighting it means either over-paying for assembly in Singapore or forgoing the high-IP advantages of a Singapore centre.

Mistaking responsiveness for a shortcut. A firm impressed by the speed at which large investments are facilitated may assume the regulatory and compliance requirements are correspondingly flexible. They are not. The agencies facilitate fitting investment efficiently; the substantive regulatory standards behind a Maturity Level 4 system are not relaxed for anyone, and a firm that confuses commercial facilitation with regulatory leniency will be unpleasantly corrected.

Reading a single output figure as a decision. A firm that lets a headline output number, chosen because it is impressive, stand in for a function-level analysis has skipped the only analysis that matters. As the divergence between the agency figure and the independent figure for 2023 shows, the headline number is a backdrop, not a basis for placing a facility.

2.13 What This Chapter Has and Has Not Settled

This chapter has set out where Singapore fits and where it does not, function by function, on the evidence of named operators and published agency figures. The strong-fit functions are early-stage and translational research, clinical-grade and high-value manufacturing, regulatory affairs and regional market access, regional distribution, and the supporting contract ecosystem. The qualified-fit functions are clinical trials, strong in early phase and weak at Phase III scale, and medical-device operations, strong for high-value devices and poor for consumables. The no-fit functions are commodity manufacturing, generic active ingredients, disposable consumables, and stand-alone large efficacy trials, all of which belong in India, Malaysia, or China.

What the chapter has not settled, and has been careful not to pretend to settle, is the practical pathway by which a European firm engages the Singapore agencies and develops the relationship that turns a fit into a facility. The published sources establish the institutions and their roles; they are silent on the texture of the engagement, and that silence is marked in this chapter rather than filled. The chapters that follow take up the components of a Singapore decision in detail: the tax and incentive framework, the regulatory pathway through the Health Sciences Authority, the land and estate system, and the staffing of a biomedical operation. Each of those rests on the function-level judgement made here. The first question was never whether Singapore is good. It was which functions belong there, and that question now has an answer the reader can put against a real case.

References

Declarations

Competing interests: The author is a licensed real estate agent (Council for Estate Agencies, Singapore) affiliated with OrangeTee & Tie Pte Ltd, and a Singapore Mediation Centre-accredited mediator. The author has commercial interests in industrial and commercial real estate transactions facilitated through OrangeTee & Tie. These interests are openly disclosed. The analysis in this chapter has been written to be useful to the reader irrespective of whether the reader subsequently engages the author’s transactional services.

Funding: This work received no external funding.

Methodology: This chapter assesses the fit of Singapore for a set of biomedical functions using two categories of evidence: the published figures and statements of Singapore’s own agencies (principally the Economic Development Board, the Health Sciences Authority, JTC Corporation, the National Medical Research Council, and the Department of Statistics), and the disclosed activities and investment decisions of named operators. Comparative cost claims for alternative locations are drawn from peer-reviewed and published analyses and are cited as such; where the comparison in a source is against a market other than Singapore, this is stated. Where agency and independent figures diverge, the divergence is reported rather than resolved in favour of the more flattering number. Where the practical pathway of engagement with the agencies is not established by primary sources, the chapter marks the gap rather than filling it.

Currency of analysis: The analysis is current as of the date of publication. Output figures, investment announcements, regulatory designations, and population figures are point-in-time and change; the Health Sciences Authority’s Maturity Level 4 designation for medical devices, in particular, dates to March 2026, and output figures are reported for 2023 as the most recent full year published at the time of writing. Readers should verify current figures against the cited primary sources before relying on them.

About the Author

David Hoicka is a Singapore-licensed real estate agent (Council for Estate Agencies) affiliated with OrangeTee & Tie Pte Ltd, with a specialisation in industrial and commercial property for European inbound investment. He is also a Singapore Mediation Centre-accredited mediator, a civil engineer (Bachelor of Science, Massachusetts Institute of Technology), and the founder and publisher of Singapore Mediation Solutions, an academic publisher registered with Crossref (DOI prefix 10.66404) and with the National Library Board of Singapore. He has lived in Singapore as a permanent resident for over twenty-one years.

Scholarly identifiers: ORCiD 0000-0001-9082-0720; Wikidata Q137455251; ISNI 0000 0005 2886 676X; Google Scholar profile available.

About the Publisher

Singapore Mediation Solutions is an open-access scholarly publisher specialising in practical and analytical works for cross-border commercial practitioners with a focus on Asia-Europe industrial and commercial relations. Singapore Mediation Solutions is registered with Crossref (DOI prefix 10.66404), is a Singapore publisher with NLB-assigned ISBNs, and deposits all works in Zenodo for permanent open-access availability and in OCLC WorldCat for library catalogue accessibility.

Confidential Consultation

Readers who would like to discuss the placement of a specific biomedical function in Singapore, and whether it sits on the fitting or the no-fit side of the boundary set out in this chapter, may contact the author directly. The preferred channels are Signal and Telegram for confidentiality and ease of cross-border communication. Direct email is also available. Contact details are listed on singaporescienceparks.com. Initial consultations are conducted without obligation; the author’s role as principal advisor and the relationship to OrangeTee & Tie transactional execution are set out in a written engagement letter before any onward referrals are made.

---

Chapter DOI: biobook-ch02 (to be assigned upon Crossref deposit) Zenodo deposit: pending Published by Singapore Mediation Solutions, Singapore Open access under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)